Platinum-based chemotherapy had a significantly higher OR for alopecia (OR 5.47, 95% CI 2.65, 11.26) than PARP inhibitor but a significantly lower OR for thrombocytopenia (OR 0.85, 95% CI 0.74, 0.99). This evidence concerns the gene PARP1 and Thrombocytopenia.